Cognition Therapeutics wins US patent for new crystalline form of zervimesine through 2045
CGTX•Cognition Therapeutics won a U.S. patent covering a new crystalline form of zervimesine, with composition-of-matter protection through 2045 and a potential FDA-related extension of up to five years. The company plans an FDA meeting next week and expects manufacturing to start in Q1 2027 for a registrational trial.
1. Patent coverage
The patent covers a new crystalline form of Cognition Therapeutics’ lead candidate zervimesine, also known as CT1812. Claims also cover a manufacturing process and treatment methods for Alzheimer’s disease, dry AMD and dementia with Lewy bodies.
2. Development plans
Management plans to meet with the FDA next week on registrational endpoints in dementia with Lewy bodies. Manufacturing of the newly patented form is slated to start in Q1 2027 for a registrational trial.
